{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-094701","form_type":"8-K","ticker":"VCNX","cik":"0001205922","company_name":"VACCINEX, INC.","filed_at":"2024-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.577444+00:00","generated_at":"2026-06-03T23:16:40.957631+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vaccinex receives Nasdaq notice for failing minimum equity requirement","bullets":["Nasdaq notice on April 11, 2024: Vaccinex lacks $2.5M minimum stockholders' equity for continued listing.","Company also fails alternative standards: market value of listed securities $35M or net income $500k.","Deadline to submit compliance plan is May 13, 2024; Nasdaq may grant extension if plan accepted.","No immediate delisting, but failure to regain compliance could lead to delisting of VCNX common stock.","Management evaluating options but cannot assure regaining or maintaining compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-094701","json":"https://secwatch.observer/filing/0001193125-24-094701.json","markdown":"https://secwatch.observer/filing/0001193125-24-094701.md","text":"https://secwatch.observer/filing/0001193125-24-094701.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1205922/000119312524094701/0001193125-24-094701-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1205922/000119312524094701/d719945d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T23:16:40.957631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"488bf2930bb956fae6fe97fba79bcad652d98939","claim":"VACCINEX, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"April 11, 2024, Vaccinex, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on the financial statements contained in its Form 10-K for the year-ended December 31, 2023, the Company no longer complies with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Equity Standard”) or the alternative requirements of having a market value of listed securities of $35 million","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1205922/000119312524094701/0001193125-24-094701-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}